Apatinib Plus Irinotecan as Second-line Treatment in AGC or EGJA

Summary

This is a prospective, multicenter, single-group clinical study of Apatinib Plus Irinotecan as second-line treatment in locally advanced or metastatic gastric or gastroesophageal junctional adenocarcinoma.

Conditions

• Metastatic Gastric Adenocarcinoma

Interventions

DRUG

Apatinib

Apatinib, a novel targeted inhibitor of VEGF receptor 2 (VEGFR2).

DRUG

Irinotecan

Irinotecan was used as second line treatment with AGC

Sponsors & Collaborators

• The First Affiliated Hospital of Dalian Medical University

  collaborator OTHER

• The Second Affiliated Hospital of Dalian Medical University

  collaborator OTHER

• Liaoning Cancer Hospital & Institute

  collaborator OTHER

• Shengjing Hospital

  collaborator OTHER

• General Hospital of Shenyang Military Region

  collaborator OTHER

• The People's Hospital of Liaoning Province

  collaborator OTHER

• Anshan Tumor Hospital

  collaborator OTHER

• Benxi Cental Hospital

  collaborator OTHER

• Liaoyang Central Hospital

  collaborator OTHER

• The Affiliated Tumor Hospital of Harbin Medical University

  collaborator UNKNOWN

• The Second Affiliated Hospital of Harbin Medical University

  collaborator OTHER

• Panjin Central Hospital

  collaborator OTHER

• Jilin University Sino-Japanese Friendship Hospital

  collaborator UNKNOWN

• The First Hospital of Jilin University

  collaborator OTHER

• Liaoyang Petrochemical General Hospital

  collaborator UNKNOWN

• China Medical University, China

  lead OTHER

Principal Investigators

• YunPeng Liu, PhD · First Hospital of China Medical University

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Max Age

70 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2017-04-05

Primary Completion

2020-03-31

Completion

2020-09-30

Countries

• China

Study Locations